Development of an Innovative Clinico-biological Score for the Early Detection of Acute Renal Failure Associated With Cardiac Surgery.

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Acute Kidney Injury
Interventions
DIAGNOSTIC_TEST

Early biomarkers of acute kidney injury

"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\],~* urinary CCL-14 \[H6\],~* plasma angiopoietin-2 \[H6\],~* plasma PENK-A \[H6\]~These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."

Trial Locations (1)

44000

Nantes UH, Nantes

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

ThermoFisher Scientific Brahms Biomarkers France

INDUSTRY

lead

Nantes University Hospital

OTHER